Cellectis S.A. Files 6-K, Incorporates Past Filings

Ticker: CLLS · Form: 6-K · Filed: May 6, 2024 · CIK: 1627281

Sentiment: neutral

Topics: reporting, regulatory-filing, registration-statement

TL;DR

Cellectis filed a 6-K, nothing new but keeps their registration statements active.

AI Summary

Cellectis S.A. filed a Form 6-K on May 6, 2024, to report information for the month of May 2024. This filing incorporates by reference previous registration statements on Form F-3 and Form S-8, indicating ongoing reporting obligations and potential future offerings. The company is based in Paris, France, and operates in the biological products sector.

Why It Matters

This filing signals ongoing regulatory compliance and potential for future capital raises or stock issuances, which could impact investors.

Risk Assessment

Risk Level: low — The filing is a routine report and does not contain new material financial or operational information that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing by Cellectis S.A.?

The primary purpose is to report information for the month of May 2024 and to incorporate by reference previous registration statements on Form F-3 and Form S-8.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed on May 6, 2024.

Where is Cellectis S.A. headquartered?

Cellectis S.A. is headquartered at 8, rue de la Croix Jarry, 75013 Paris, France.

Which registration statements are being incorporated by reference in this filing?

Registration statements on Form F-3 (No. 333-265826) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760 and 333-273777) are incorporated by reference.

Does Cellectis S.A. file annual reports under Form 20-F or Form 40-F?

Cellectis S.A. files annual reports under cover of Form 20-F, as indicated by the checkmark in the filing.

Filing Stats: 215 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2024-05-06 06:00:09

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: May 6, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing